Vertex's povetacicept met its Phase 3 primary endpoint in IgA nephropathy (IgAN) with a 50-52% reduction in proteinuria versus placebo after 36 weeks12.
The drug showed positive secondary endpoints, including reduction in abnormal antibodies and hematuria resolution, with mostly mild side effects like respiratory infections1.
Vertex plans to complete its accelerated FDA approval application by end of March 2026 using a priority review voucher for a 6-month review12.
Analysts see multibillion-dollar potential, with povetacicept outperforming Otsuka's Voyxact on proteinuria, but eGFR data at 2 years will be key for long-term efficacy and competition12.
Vertex stock rose nearly 9% post-announcement on March 9, 2026, reflecting market enthusiasm for this kidney drug beyond its CF franchise12.
While promising, full differentiation from competitors like Vera Therapeutics awaits confirmatory eGFR results later in 20261.
Sources:
1. https://www.biopharmadive.com/news/vertex-povetacicept-iga-nephropathy-study-results/814253/
2. https://www.ainvest.com/news/vertex-march-fda-deadline-catalyst-unlock-4-billion-kidney-drug-bet-2603/